patient reported outcomes
Recently Published Documents





2022 ◽  
Vol 48 (1) ◽  
pp. 15-29
Christina K. Zigler ◽  
Rachel L. Randell ◽  
Bryce B. Reeve

Oral Oncology ◽  
2022 ◽  
Vol 125 ◽  
pp. 105701
Adrian I. Mendez ◽  
Jacob G.J. Wihlidal ◽  
Dean T. Eurich ◽  
Anthony C. Nichols ◽  
S. Danielle MacNeil ◽  

2022 ◽  
Vol 270 ◽  
pp. 348-358
Adrienne N. Christopher ◽  
Martin P Morris ◽  
Viren Patel ◽  
Robyn B. Broach ◽  
John P. Fischer

2022 ◽  
pp. jrheum.200609
Majed Mustafa Khraishi ◽  
Valencia P. Remple ◽  
Samuel Silverberg ◽  
Jacqueline C. Stewart ◽  
Brandusa Florica ◽  

Objective COMPLETE-PsA was an observational study of biologic-naïve Canadian adults with active psoriatic arthritis (PsA) treated with adalimumab or a non-biologic disease-modifying antirheumatic drug (nbDMARDs) regimen, after inadequate response/intolerance to a current nbDMARD treatment regimen. The aim of this analysis was to assess 12-month effectiveness of adalimumab versus nbDMARDs. Methods Patients enrolled between March 2012 and November 2017 were included. The following clinical parameters and patient-reported outcomes were collected/calculated per routine care: DAPSA28, DAS28, ESR, CRP, MDGA, PtGA, pain, HAQ-DI, SF-12, enthesitis, dactylitis, BSA, and time to achieving ACR50, ACR70 and modified MDA (mMDA). Results Two hundred seventy-seven adalimumab-treated and 148 nbDMARD-treated patients were included. At baseline, adalimumab-treated patients were less likely to be employed; had longer morning stiffness; higher DAPSA28, DAS28, MDGA, PtGA, pain, and HAQ-DI; and lower prevalence of dactylitis (all p<0.05). Adalimumab-treated patients showed lower baseline-adjusted DAPSA28 (16.5 vs. 26.6), DAS28 (2.8 vs. 3.9), MDGA (25.3 vs. 37.1), and ESR (10.2 vs. 15.4 mm/hr) after 3 months compared to nbDMARD-treated patients, with observed improvements maintained to month 12. Time to achievement of ACR50, ACR70, and mMDA was significantly (p<0.01) shorter among adalimumab-treated patients, with the likelihood of having dactylitis [OR: 0.4 (0.2–0.6)] and BSA<3% [2.7 (1.5–5.0)] significantly lower and higher, respectively. Switching to another biologic was less likely in adalimumab-treated vs. nbDMARD -treated patients (HR [95% CI]: 0.3 [0.2-0.5]). Conclusion In a real-world Canadian PsA population, adalimumab was more effective than nbDMARDs at reducing disease activity and the severity of skin involvement and demonstrated higher retention.

Sign in / Sign up

Export Citation Format

Share Document